Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25059246 | 0.86 | ACACB (0.34) | ACACB | |
| SCHEMBL26328570 | 0.85 | ACACB (0.34) | ACACB | |
| SCHEMBL18591835 | 0.85 | ACACB (0.34) | ACACB | |
| SCHEMBL25053676 | 0.82 | ACACB (0.36) | GRM5ACACBALOX5IDO1KCNH2 | |
| SCHEMBL20325131 | 0.80 | GRM5 (0.35) | GRM5ACACBALOX5KCNH2 | |
| SCHEMBL22692186 | 0.73 | ACACB (0.42) | GRM5ACACBIDO1KCNH2 | |
| SCHEMBL18551308 | 0.70 | ACACB (0.40) | ACACB | |
| SCHEMBL18612041 | 0.70 | HTR2A (0.33) | KCNH2 | |
| SCHEMBL18551220 | 0.69 | ACACB (0.34) | ACACB | |
| SCHEMBL26748745 | 0.69 | ACACB (0.39) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20190233433-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | GRM5 1580/4885ACACB 3205/4885ALOX5 3996/4885 |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | GRM5 630/4885ACACB 1442/4885ALOX5 4022/4885 |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | GRM5 630/4885ACACB 1442/4885ALOX5 4022/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | GRM5 1580/4885ACACB 3205/4885ALOX5 3996/4885 |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | GRM5 1204/4885ACACB 1591/4885ALOX5 3924/4885 |
| US-20190233433-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | GRM5 3195/4885ACACB 3977/4885ALOX5 4744/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | GRM5 1204/4885ACACB 1591/4885ALOX5 3924/4885 |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | GRM5 3132/4885ACACB 2983/4885ALOX5 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.